Sharad Pawar says final draft will go to Cabinet before Tuesday.
Company refuses to comment, says 'matters internal to organisation'
Action is hotting up in the telecom space, with Russian giant Sistema in preliminary discussions with Aircel to pick up an equity stake.
Another cap for imported insulin; domestic manufacturers cry foul.
Though reserve for CDMA, there were no bidders for the spectrum in the recent auction. GSM operators could buy it to launch 4G and 3G services.
FinMin had objected and wanted existing cost-plus method retained.
CCI to examine competition part of deals, RBI prudential aspects.
A large migrant population, better law and order situation made the state attractive.
Work to begin after that on corrective measures to meet US regulator's requirements.
Multiple disputes to ensue; auction begins today, but will do little to quell uncertainty.
After refarming, over 142.5 MHz of spectrum is expected to be available for auctioning next year.
USFDA has extended the timeline for granting tentative approval to generic drug applications filed under Para IV of its rules by 10 months.
Sun Pharma could have to withdraw cancer drug as J&J re-enters after temporary eclipse
Govt to bear Rs 12k-cr cost of spectrum retention but without any cash outgo put up for Cabinet nod.
Now, the companies need to get National Pharmaceutical Pricing Authority's nod for changing medicine composition. If they flout norms, government will take penal action.
A senior executive of GMR group confirmed that both the companies were keen to get out of the venture. Fraport has already closed its development office in India.
Bharat Sanchar Nigam Ltd (BSNL) and Mahanagar Telephone Nigam Ltd (MTNL) have sent separate letters to the department of telecommunications (DoT), asking the government to bear the entire burden of nearly Rs 11,000 crore they need to fork out as one-time payment for additional spectrum.
GoM had proposed a new pricing mechanism, but judges had said at an earlier hearing the current formula should stay.
Ranbaxy was scheduled to launch its drug on September 21, the day Diovan's patent expired.
The move is significant, as this may prompt investigating agencies to take a look at the fresh accounting statements to be filed by the company to RoC, before taking a final call.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances